Alemtuzumab suppresses MRI disease activity over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II)

Authors
Category Primary study
JournalMultiple Sclerosis
Year 2016
This article has no abstract
Epistemonikos ID: 4d87edb512bc63d067855a80dd980238a6ee8180
First added on: Feb 07, 2025